课件：转移性结直肠癌治疗的新进展_.pptVIP

下载本文档

41
0
约3.41万字
约 72页
2019-02-22 发布于广东
举报
版权申诉

课件：转移性结直肠癌治疗的新进展_.ppt

1、有哪些信誉好的足球投注网站（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

课件：转移性结直肠癌治疗的新进展_.ppt

* New Developments in the Treatment of Colorectal Cancer * * * FOLFOX, 5-fluorouracil, leucovorin, and oxaliplatin; mFOLFOX, modified 5-fluorouracil, leucovorin, and oxaliplatin; sLV5FU2, simplified leucovorin plus bolus and infusional fluorouracil. * OS, overall survival; PFS, progression-free survival. * * * * ECOG, Eastern Cooperative Oncology Group; mCRC, metastatic colorectal cancer; PS, performance score; q3w, every 3 weeks. * * * Bev, bevacizumab; ITT, intention to treat; XELOX, capecitabine, oxaliplatin. * CR, complete response; FOLFIRI, leucovorin/fluorouracil/irinotecan; mCRC, metastatic colorectal cancer; PR, partial response; SD, stable disease. * * OS, overall survival; PFS, progression-free survival. * * 5-FU, 5-fluorouracil; ECOG, Eastern Cooperative Oncology Group; FOLFOX4, 5-fluorouracil, oxaliplatin, leucovorin; IV, intravenously; LV, leucovorin; mCRC, metastatic colorectal cancer; q2w, every 2 weeks; XRT, external-beam radiotherapy. * * Bev, bevacizumab; FOLFOX4, 5-fluorouracil, oxaliplatin, leucovorin; mCRC, metastatic colorectal cancer; OS, overall survival. * * 5-FU, 5-fluorouracil; BEV, bevacizumab; CT, chemotherapy; ECOG PS, Eastern Cooperative Oncology Group performance status; mCRC, metastatic colorectal cancer; OS, overall survival; PD, progressive disease; PFS, progression-free survival. * CT, chemotherapy; BEV, bevacizumab; ECOG, Eastern Cooperative Oncology Group; ITT, intent to treat; OS, overall survival; PFS, progression-free survival; PS, performance score. * * * * ECOG, Eastern Cooperative Oncology Group; FOLFIRI, fluorouracil/leucovorin/irinotecan; mCRC, metastatic colorectal cancer; ORR, overall response rate; OS, overall survival; q2w, once every 2 weeks; PFS, progression-free survival; PS, performance status. * * FOLFIRI, fluorouracil/leucovorin/irinotecan; mCRC, metastatic colorectal cancer; OS, overall survival; PFS, progression-free survival. * * AFL, aflibercept; FOLFIRI, fluorouracil/leucovorin/irin